echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Demystifying the pathogenesis of aortic dissection from the perspective of single cells——The research results of Zhang Tao's research group from the Department of Vascular Surgery, Peking University People's Hospital are published in an authoritative academic journal

    Demystifying the pathogenesis of aortic dissection from the perspective of single cells——The research results of Zhang Tao's research group from the Department of Vascular Surgery, Peking University People's Hospital are published in an authoritative academic journal

    • Last Update: 2022-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, new discoveries have been made about the pathogenesis of aortic dissection (AD)


    Innovative research articles published in Theranostics journals focus on in vitro diagnostics and prognosis, in vivo molecular imaging, molecular therapy, image-guided therapy, biosensors, systems biology and translational medicine, personalized medicine, and a wide range of biomedical research areas, which can be applied to Future Therapeutic Diagnostic Applications


    Aortic dissection (AD), which can occur at any age, is one of the most common, complex and dangerous aortic diseases in clinical practice


    The aorta is the largest arterial vessel and is divided into three layers: adventitia, media and intima.


    According to studies, the pathogenesis of AD is mainly based on the abnormal structure of the medial membrane, that is, the degeneration of smooth muscle cells


    Zhang Tao's group focuses on exploring cell-to-cell interactions and functional targets in vascular homeostasis and disease development


    This study proves the feasibility of treating AD from the perspective of regulating the interaction between cells, which not only provides a new idea for the treatment of AD in the future, but also finds a new target for the drug treatment of AD in the future, that is, inhibition of fibroblasts.









    Some research data and graphs

    This research was supported by the National Natural Science Foundation of China and the National Key R&D Program Fund Project


    Attachment: Author brief introduction

    Zhang Tao, Chief Physician, Associate Professor, Doctoral Supervisor, Assistant of the Department of Vascular Surgery, Peking University People's Hospital


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.